Please login to the form below

Not currently logged in
Email:
Password:

Bayer UK and Ireland appoints new CEO

Lars Bruening succeeds Alex Moscho

Lars BrueningBayer has appointed a new UK and Ireland CEO in the form of Lars Bruening, who moves to its Reading, UK base from Berlin where he was head of the pharma group’s global market access business.

Prior to that Bruening held senior commercial roles in Europe, the Middle East and Asia, bringing knowledge in the pharmaceutical sector, international healthcare landscape and global commercial markets to the group.

He said: “Looking in from afar, the progress the UK and Ireland has made over the last four years alone, with the UK becoming the third largest Bayer market in Europe and the eighth largest in the world, as well as the progress made in individual markets also reflects the ongoing work with our partners and colleagues at the grassroots levels.

“It is this, which I am incredibly proud of and look forward to building upon this existing success.”

Bruening succeeds Alexander Moscho, who left Bayer after seven years to join UCB as its chief strategy officer.

16th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics